Modelling HIV-1 2-LTR dynamics following raltegravir intensification

Journal of the Royal Society Interface

Volumn 10, Issue 84, 2013, Pages

  Luo, Rutao ^a   Cardozo, E Fabian ^a   Piovoso, Michael J ^b   Wu, Hulin ^c   Buzon, Maria J ^d,f   Martinez Picado, Javier ^d,e   Zurakowski, Ryan ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b The Center for Nanotechnology Education and Utilization   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d IrsiCaixa Foundation   (Spain)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^f Ragon Institute   (United States)

Author keywords

Cryptic viremia; HIV; Mathematical biology

Indexed keywords

CELLS; CYTOLOGY; HOSPITAL DATA PROCESSING; PATIENT TREATMENT; VIRUSES;

CONFIDENCE INTERVAL; CRYPTIC VIREMIA; HIV; HIV INTEGRASE INHIBITORS; MATHEMATICAL BIOLOGY; MODEL PARAMETERS; RANDOM MEASUREMENT; VIRAL REPLICATION;

DISEASES;

RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; CIRCULAR DNA; VIRUS DNA;

ARTICLE; CELL ACTIVATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION RATE; MATHEMATICAL MODEL; NONHUMAN; NULL HYPOTHESIS; PARAMETERS; REAL TIME POLYMERASE CHAIN REACTION; VIRUS REPLICATION; BIOLOGICAL MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTIC VIREMIA; DISEASE CARRIER; DRUG EFFECT; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL BIOLOGY; METABOLISM; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CRYPTIC VIREMIA; HIV; MATHEMATICAL BIOLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE RESERVOIRS; DNA, CIRCULAR; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; PYRROLIDINONES; TIME FACTORS; VIRUS REPLICATION;

EID: 84878666650     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2013.0186     Document Type: Article

References (73)

1. Hatano H, Vogel S, Yoder C, Metcalf JA, Dewar R, Davey RT, Polis MA. 2000 Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. AIDS 14, 1357-1363. (doi:10.1097/00002030-200007070-00008)
2. Chun TW, Davey RT, Ostrowski M, Shawn Justement J, Engel D, Mullins JI, Fauci AS. 2000 Relationship between pre-existing viral reservoirs and the reemergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 6, 757-761. (doi:10.1038/77481)
3. Chun TW, Davey RT, Engel D, Lane HC, Fauci AS. 1999 Re-emergence of HIV after stopping therapy. Nature 401, 874-875. (doi:10.1038/44755)
4. Davey R et al. 1999 HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl Acad. Sci. USA 96, 15 109-15 114. (doi:10.1073/pnas.96.26.15109)
5. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. 1997 Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295. (doi:10.1126/science.278. 5341.1291)
6. Palmer S et al. 2003 New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41, 4531-4536. (doi:10.1128/JCM.41.10.4531-4536. 2003)
7. Trono D, Van Lint C, Rouzioux C, Verdin E, Barré-Sinoussi F, Chun TW, Chomont N. 2010 HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329, 174-180. (doi:10.1126/science.1191047)
8. Hatano H et al. 2010 Evidence of persistent lowlevel viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 24, 2535-2539. (doi:10.1097/QAD.0b013e32833dba03)
9. Nettles RE et al. 2005 Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 293, 817-829. (doi:10.1001/jama. 293.7.817)
10. Persaud D et al. 2004 Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J. Virol. 78, 968-979. (doi:10.1128/JVI.78.2. 968-979.2004)
11. Maldarelli F et al. 2007 ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathogens 3, e46. (doi:10.1371/journal.ppat.0030046)
12. Dornadula G et al. 1999 Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282, 1627-1632. (doi:10.1001/jama.282.17.1627)
13. Josefsson L, Dahl V, Palmer S. 2010 Can HIV infection be eradicated through use of potent antiviral agents? Curr. Opin. Infect. Dis. 23, 628-632. (doi:10.1097/QCO.0b013e32833ff1d0)
14. Maldarelli F. 2011 Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication. Curr. Opin. HIV AIDS 6, 49-56. (doi:10.1097/COH.0b013e32834134ea)
15. Siliciano JD, Siliciano RF. 2010 Biomarkers of HIV replication. Curr. Opin. HIV AIDS 5, 491-497. (doi:10.1097/COH.0b013e32833f206f)
16. Tobin NH et al. 2005 Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J. Virol. 79, 9625-9634. (doi:10.1128/JVI.79.15.9625-9634.2005)
17. Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. 2011 Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathogens 7, e1001303. (doi:10.1371/journal.ppat.1001303)
18. Cohen J. 2011 HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts. Science 334, 1614. (doi:10.1126/science.334.6063. 1614)
19. Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, Goujard C, Rouzioux C, Taoufik Y, Delfraissy J-F. 2004 The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 18, 1147-1158. (doi:10.1097/00002030-200405210-00008)
20. Cintrón-Arias A, Castillo-Chávez C, Bettencourt LMA, Lloyd AL, Banks HT. 2009 The estimation of the effective reproductive number from disease outbreak data. Math. Biosci. Eng. 6, 261-282. (doi:10.3934/mbe.2009.6. 261)
21. + T cells. J. Virol. 85, 5220-5223. (doi:10.1128/JVI.00284-11)
22. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, Ray SC, Persaud D, Siliciano R. 2004 Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J. Infect. Dis. 189, 1452-1465. (doi:10.1086/382488)
23. Hermankova M et al. 2001 HIV-1 drug resistance profiles in children and adults with viral load of < 50 copies/mL receiving combination therapy. JAMA 286, 196-207. (doi:10.1001/jama.286.2.196)
24. + T cells. J. Virol. 80, 6441-6457. (doi:10.1128/JVI.00591-06)
25. Evering TH, Mehandru S, Racz P, Tenner-Racz K, Poles MA, Figueroa A, Mohri H, Markowitz M, Malim MH. 2012 Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathogens 8, e1002506. (doi:10.1371/journal.ppat.1002506)
26. Dinoso JB et al. 2009 Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 106, 9403-9408. (doi:10.1073/pnas.0903107106)
27. McMahon D et al. 2010 Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin. Infect. Dis. 50, 912-919. (doi:10.1086/650749)
28. Gandhi RT et al. 2012 No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 59, 229-235. (doi:10.1097/QAI.0b013e31823fd1f2)
29. Pauza CD, Trivedi P, McKechnie TS, Richman DD, Graziano FM. 1994 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. Virology 205, 470-478. (doi:10.1006/viro.1994.1667)
30. Sharkey ME et al. 2000 Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 6, 76-81. (doi:10.1038/71569)
31. Morlese J, Teo IA, Choi JW, Gazzard B, Shaunak S. 2003 Identification of two mutually exclusive groups after long-term monitoring of HIV DNA 2-LTR circle copy number in patients on HAART. AIDS 17, 679-683. (doi:10.1097/00002030- 200303280-00005)
32. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. 2002 Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J. Virol. 76, 4138-4144. (doi:10.1128/JVI.76.8.4138- 4144.2002)
33. Butler SL, Johnson EP, Bushman FD. 2002 Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J. Virol. 76, 3739-3747. (doi:10.1128/JVI.76.8.3739-3747.2002)
34. Bushman F. 2003 Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker. AIDS 17, 749-750. (doi:10.1097/00002030-200303280-00014)
35. Zhu W et al. 2011 Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy. PLoS ONE 6, e21081. (doi:10.1371/journal. pone.0021081)
36. Buzón MJ et al. 2010 HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 16, 460-465. (doi:10.1038/nm.2111)
37. Llibre JM et al. 2012 Treatment intensification with raltegravir in subjects with sustained HIV-1 viremia suppression: a randomized 48 weeks study. Antivir. Ther. (Lond.) 17, 355-364. (doi:10.3851/IMP1917)
38. Murray JM. 2009 HIV dynamics and integrase inhibitors. Antivir. Chem. Chemother. 19, 157-164.
39. Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, Nguyen BT, Teppler H, Cooper DA. 2007 Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 21, 2315-2321. (doi:10.1097/QAD.0b013e3282f12377)
40. + T cells. Math. Biosci. 114, 81-125. (doi:10.1016/0025-5564(93)90043-A)
41. Sedaghat AR, Siliciano RF, Wilke CO. 2009 Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. Antivir. Ther. (Lond.) 14, 263-271.
42. Cardozo EF, Vargas CA, Zurakowski R. 2012 A compartment based model for the formation of 2-LTR circles after raltegravir intensification. In 51st IEEE Conf. on Decision and Control, Maui, HI, USA, 10-13 December 2012, pp. 4924-4929. (doi:10.1109/CDC.2012.6426088)
43. Crosley LK et al. 2009 Variation in protein levels obtained from human blood cells and biofluids for platelet, peripheral blood mononuclear cell, plasma, urine and saliva proteomics. Genes Nutr. 4, 95-102. (doi:10.1007/s12263- 009-0121-x)
44. Colgrove R, Japour A. 1999 A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. Antivir. Res. 41, 45-56. (doi:10.1016/S0166-3542(98)00062-X)
45. Armbruster DA, Pry T. 2008 Limit of blank, limit of detection and limit of quantitation. Clin. Biochem. Rev. 29(Suppl. 1), S49-S52.
46. Perrin L, Pawlotsky JM, Bouvier-Alias M, Sarrazin C, Zeuzem S, Colucci G. 2006 Multicenter performance evaluation of a new TaqMan PCR assay for monitoring human immunodeficiency virus RNA load. J. Clin. Microbiol. 44, 4371-4375. (doi:10.1128/JCM.00505-06)
47. Bengtsson M, Hemberg M, Rorsman P, Ståhlberg A. 2008 Quantification of mRNA in single cells and modelling of RT-qPCR induced noise. BMC Mol. Biol. 9, 63. (doi:10.1186/1471-2199-9-63)
48. Luo R, Piovoso MJ, Zurakowski R. 2012 Modeling uncertainty in single-copy assays for HIV. J. Clin. Microbiol. 50, 3381-3382. (doi:10.1128/JCM.01254-12)
49. Tobin J. 1958 Estimation of relationships for limited dependent variables. Econometrica 26, 24-36. (doi:10.2307/1907382)
50. Tse E, Anton JJ. 1972 On the identifiability of parameters. IEEE Trans. Autom. Control 17, 637-646. (doi:10.1109/TAC.1972.1100091)
51. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS, Ho DD. 2003 A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol. 77, 5037-5038. (doi:10.1128/JVI.77.8.5037-5038.2003)
52. Vonesh EF, Chinchilli VM. 1997 Linear and nonlinear models for the analysis of repeated measurements, vol. 154. Statistics: Textbooks and Monographs. New York, NY: Marcel Dekker Inc.
53. Davidian M, Giltinan DM. 1995 Nonlinear models for repeated measurement data, 1st edn. Monographs on Statistics & Applied Probability. New York, NY: Chapman and Hall/CRC.
54. Wu H. 2005 Statistical methods for HIV dynamic studies in AIDS clinical trials. Stat. Methods Med. Res. 14, 171-192. (doi:10.1191/0962280205sm390oa)
55. Bortz D. 2006 Model selection and mixed-effects modeling of HIV infection dynamics. Bull. Math. Biol. 68, 2005-2025. (doi:10.1007/s11538-006-9084-x)
56. Wu L, Wu H. 2002 Missing time-dependent covariates in human immunodeficiency virus dynamic models. J. R. Stat. Soc. Ser. C 51, 297-318. (doi:10.1111/1467-9876.00270)
57. Huang Y, Wu H, Acosta EP. 2010 Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors. Biomet. J. 52, 470-486. (doi:10.1002/bimj.200900173)
58. Samson A, Lavielle M, Mentr F. 2006 Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Comput. Stat. Data Anal. 51, 1562-1574. (doi:10.1016/j.csda.2006.05.007)
59. Wu H, Zhao C, Liang H. 2004 Comparison of linear, nonlinear and semiparametric mixed-effects models for estimating HIV dynamic parameters. Biomet. J. 46, 233-245. (doi:10.1002/bimj.200310019)
60. Putter H, Heisterkamp SH, Lange JMA, de Wolf F. 2002 A Bayesian approach to parameter estimation in HIV dynamical models. Stat. Med. 21, 2199-2214. (doi:10.1002/sim.1211)
61. Luo R, Piovoso MJ, Martinez-Picado J, Zurakowski R. 2012 HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics. PLoS ONE 7, e40198. (doi:10.1371/journal.pone.0040198)
62. Han C, Chaloner K, Perelson A. 2002 Bayesian analysis of a population HIV dynamic model. In Case studies in Bayesian statistics (eds C Gatsonis et al.), pp. 223-237. New York, NY: Springer.
63. + cell line. Virol. J. 7, 354. (doi:10.1186/1743-422X-7-354)
64. Reigadas S, Andréola ML, Wittkop L, Cosnefroy O, Anies G, Recordon-Pinson P, Thiebaut R, Masquelier B, Fleury H. 2010 Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. J. Antimicrob. Chemother. 65, 434-437. (doi:10.1093/jac/dkp473)
65. DiStefano JI, Cobelli C. 1980 On parameter and structural identifiability: nonunique observability/reconstructibility for identifiable systems, other ambiguities, and new definitions. IEEE Trans. Autom. Control 25, 830-833. (doi:10.1109/TAC.1980.1102439)
66. Miao H, Dykes C, Demeter L, Wu H. 2009 Differential equation modeling of HIV viral fitness experiments: model identification, model selection, and multimodel inference. Biometrics 65, 292-300. (doi:10.1111/j.1541-0420.2008. 01059.x)
67. Wu H, Zhu H, Miao H, Perelson AS. 2008 Parameter identifiability and estimation of HIV/AIDS dynamic models. Bull. Math. Biol. 70, 785-799. (doi:10.1007/s11538-007-9279-9)
68. Miao H, Xia X, Perelson AS, Wu H. 2011 On identifiability of nonlinear ODE models and applications in viral dynamics. SIAM Rev. 53, 3-39. (doi:10.1137/090757009)
69. Besson GJ, McMahon D, Maldarelli F, Mellors JW. 2012 Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin. Infect. Dis. 54, 451-453. (doi:10.1093/cid/cir721)
70. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD. 1997 In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J. Virol. 71, 2059-2071. (Pubitemid 27078584)
71. Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, Ho DD. 1996 Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J. Virol. 70, 3098-3107. (Pubitemid 26121927)
72. Yukl SA et al. 2010 Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 24, 2451-2460. (doi:10.1097/QAD. 0b013e32833ef7bb)
73. Buzón MJ et al. 2011 Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathogens 7, e1002314. (doi:10.1371/journal.ppat.1002314)